Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Laura M. Spring et al.|Clinical Cancer Research|2024Cited by 43
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerBogang Wu, Leif W. Ellisen, Win Thant et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast CancerAditya Bardia, Leif W. Ellisen, Sheng Sun et al.|Unknown|2024Cited by 1